# Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

> **NCT06372483** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **VarmX B.V.** · enrollment: 40 (actual)

## Conditions studied

- Coagulation Disorder

## Interventions

- **DRUG:** VMX-C001
- **DRUG:** Placebo
- **DRUG:** Rivaroxaban 20 mg Oral Tablet
- **DRUG:** Apixaban 5 mg Oral Tablet
- **DRUG:** Edoxaban 60 mg Oral Tablet

## Key facts

- **NCT ID:** NCT06372483
- **Lead sponsor:** VarmX B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-21
- **Primary completion:** 2024-08-07
- **Final completion:** 2026-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372483, "Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06372483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*